Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
- 60% of Respondents Are Unaware That Colorectal Cancer is Asymptomatic Ill: Survey
July 9, 2012
- OPIR Says Surplus of Drug Imports “Unrelated to International Competitiveness of Domestic Industry”
July 6, 2012
- JPMA Calls for Restoration of 30% Maximum Deduction Rate in R&D Tax Credit System
July 4, 2012
- 30% of Medical Institutions Introduce Generic Name Prescribing: Yakukeiren Survey
July 3, 2012
- JGA Begins Posting Information on Out-of-Stock Products, Delayed Shipments on Website
July 3, 2012
- JPA Vice President Miura Calls for Discussions on Role of Pharmacies; Raises Question about Dividends Paid by Listed Pharmacies
June 27, 2012
- Legal Prescription Receipt Rate at Record-High 64.6% in FY2011: JPA
June 26, 2012
- JPWA, NPhA Confirm Need for Thorough Efforts “at Ground Level” for Distribution Improvements
June 25, 2012
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
- Astellas’ Nogimori New Acting President of IFPMA
June 18, 2012
- NPhA Survey: Nearly Half of Pharmacy Operators Have Received No Price Offers from Wholesalers
June 18, 2012
- Generic Market Share Increases Marginally to 23.3% in FY2011: JGA
June 18, 2012
- Drugs Developed in Response to Gov’t Request Should Be Exempted from Downward Foreign Average Price Adjustment: FPMAJ
June 13, 2012
- 48 Products Subjected to Market Expansion Re-Pricing in FY2012: FPMAJ Survey
June 13, 2012
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
- FPMAJ’s NHI Drug Price Study Committee to Set Up Task Forces for Long-Listed Products, Cost Effectiveness
June 11, 2012
- Chairman Kamoya of FPMAJ’s Committee on NHI Drug Pricing Expresses Concern Over Long-Listed Drugs
June 11, 2012
- JAPMS to Establish Working Group on Improvement of Drug Distribution
June 6, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…